早期がん検出・モニタリング用リキッドバイオプシー市場規模、シェア、動向分析レポート：バイオマーカー別、技術別、がん別、最終用途別、地域別、セグメント別予測、2025年～2033年

早期がん検出・モニタリング用リキッドバイオプシー市場概要

早期がん検出・モニタリング用リキッドバイオプシーの世界市場規模は、2024年に22億3,000万米ドルと推定され、2033年には62億米ドルに達すると予測され、2025～2033年のCAGRは12.14%で成長すると予測されます。この市場は、さまざまながんを早期かつ正確に検出し、タイムリーな介入と患者の転帰の改善を可能にするために設計された診断ソリューションに焦点を当てています。

このセグメントの技術には、体液から循環腫瘍DNA（ctDNA）、循環腫瘍細胞（CTC）、その他のバイオマーカーを分析するプラットフォームが含まれ、組織バイオプシーに代わる侵襲性の低い方法を提供しています。これらのソリューションは、早期発見、治療法の選択、疾患モニタリングのために、臨床と研究環境全体にわたって、ますます腫瘍学診療に組み込まれるようになってきています。

リキッドバイオプシーの採用は、がん罹患率の上昇と、患者への不快感を最小限に抑えながら頻繁なモニタリングを可能にする非侵襲的手法へのニーズの高まりに支えられています。腫瘍に関連した遺伝子の変化をリアルタイムで検出する能力は、治療方針の決定や早期介入戦略のための貴重な情報を腫瘍医に記載しています。

さらに、リキッドバイオプシーの採用は、ゲノムと分子レベルでの知見が治療決定や長期的ケアに反映されるプレシジョン・オンコロジーへの移行に伴って増加しています。次世代シーケンス、デジタルPCRワークフロー、進歩するバイオインフォマティクスツールによってサポートされる高感度技術は、低頻度変異、微小残存病変、新たな耐性シグナルを検出するのに役立ちます。さらに、DNA、RNA断片、エピジェネティックシグネチャー、細胞外小胞内容物など複数のバイオマーカーを分析するマルチがん早期検出とアッセイパネルの取り組みにより、後期管理からリスク評価と集団レベルのスクリーニングまで臨床応用の幅が広がっています。

さらに、従来型組織ベース手法と比較して臨床的価値と費用対効果に焦点を当てたエビデンス創出プログラム、規制当局の支援、支払者の評価によって市場は形成されています。プラットフォームによるアッセイ性能のばらつき、サンプル採取と分析における標準化の欠如、初期病期における弱いシグナルの解釈の困難さなど、課題は依然として存在します。地域によっては償還が限られていることも、利用しやすさに影響しています。現在進行中の臨床検査、実臨床検査、データ共有の取り組みにより、早期発見と継続的ながんモニタリングのためのリキッドバイオプシーが明確になり、ガイドラインが改善され、より広く採用されることが期待されます。

早期発見とモニタリングのためのリキッドバイオプシーにおける技術革新は、精度、利用しやすさ、臨床応用性を重視します。マルチオミクスの統合、AI主導の解釈、先進的シーケンスが検出と追跡のプロセスを変革し、早期疾患に対するより高い感度と、より個別化された治療計画を可能にします。

マルチがん検出アッセイやニアペイシェントプラットフォームなどの開発は、リキッドバイオプシーを集中施設の外にまで拡大し、利便性を高め、大規模なスクリーニングイニシアチブを支援することを目指しています。微小残存病変の検出と継続的モニタリングの進展は、より広範な臨床への導入を促進し、がん医療におけるリキッドバイオプシーの役割を強化すると予想されます。

目次

第1章 早期がん検出・モニタリング用リキッドバイオプシー市場：調査手法と範囲

第2章 早期がん検出・モニタリング用リキッドバイオプシー市場：エグゼクティブサマリー

• 市場スナップショット
• バイオマーカーと技術のスナップショット
• がんスナップショット
• 最終用途スナップショット
• 競合情勢のスナップショット

第3章 早期がん検出・モニタリング用リキッドバイオプシー市場の変数、動向、範囲

• 市場セグメンテーションと範囲
• 市場系統の展望
  • 親市場の展望
  • 関連/補助市場展望
• 市場力学
• 市場促進要因分析
  • 非侵襲性がん検査の需要増加
  • 先進技術の統合
  • 臨床採用と規制承認の増加
• 市場抑制要因分析
  • リキッドバイオプシー検査とインフラの高コスト
  • 分析と臨床検証の課題
• ポーターのファイブフォース分析
• PESTLE分析
• パイプライン分析

第4章 早期がん検出・モニタリング用リキッドバイオプシー市場：バイオマーカー別、推定・動向分析

• 早期がん検出・モニタリング用リキッドバイオプシー市場：バイオマーカー変動分析
• 循環腫瘍DNA（CtDNA）
• 循環腫瘍細胞（CTC）
• エクソソーム/マイクロベシクル
• 循環タンパク質

第5章 早期がん検出・モニタリング用リキッドバイオプシー市場：技術推定・動向分析

• 早期がん検出・モニタリング用リキッドバイオプシー市場：技術変動分析
• NGS（次世代シーケンス）
• PCRベースアッセイ（デジタルPCR、RT-PCR）
• マイクロアレイ
• エピゲノミクス/メチル化アッセイ
• その他

第6章 早期がん検出・モニタリング用リキッドバイオプシー市場：がん別、推定・動向分析

• 早期がん検出・モニタリング用リキッドバイオプシー市場：がん変動分析
• 肺がん
• 乳がん
• 大腸がん
• 前立腺がん
• その他

第7章 早期がん検出・モニタリング用リキッドバイオプシー市場：最終用途別、推定・動向分析

• 早期がん検出・モニタリング用リキッドバイオプシー市場：最終用途変動分析
• 病院
• 診断ラボ
• その他

第8章 早期がん検出・モニタリング用リキッドバイオプシー市場：地域ビジネス分析

• 地域市場のスナップショット
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

第9章 競合情勢

• 企業分類
• 戦略マッピング
  • 新しいバイオマーカーの発売
  • パートナーシップ
  • 取得
  • コラボレーション
  • 資金調達
• 主要企業の市場シェア分析（2024年）
• 企業ヒートマップ分析
• 企業プロファイル
  • Grail, Inc.
  • Exact Sciences Corporation
  • Anchordx
  • Burning Rock BIoTech Limited
  • Genecast
  • Guardant Health
  • Myriad Genetics, Inc.
  • Elypta Ab
  • Lucence Health Inc.
  • Freenome Holdings, Inc.
  • Oncimmune

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviation
• Table 3 Global liquid biopsy for early cancer detection and monitoring market, by region, 2021 - 2033 (USD Million)
• Table 4 Global liquid biopsy for early cancer detection and monitoring market, By Cancer, 2021 - 2033 (USD Million)
• Table 5 Global liquid biopsy for early cancer detection and monitoring market, By Biomarker, 2021 - 2033 (USD Million)
• Table 6 Global liquid biopsy for early cancer detection and monitoring market, By Technology, 2021 - 2033 (USD Million)
• Table 7 Global liquid biopsy for early cancer detection and monitoring market, By End Use, 2021 - 2033 (USD Million)
• Table 8 North America Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Country, 2021 - 2033 (USD Million)
• Table 9 North America Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Cancer, 2021 - 2033 (USD Million)
• Table 10 North America Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Biomarker, 2021 - 2033 (USD Million)
• Table 11 North America Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Technology, 2021 - 2033 (USD Million)
• Table 12 North America Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
• Table 13 U.S. Liquid Biopsy for Early Cancer Detection and Monitoring Market, by Cancer, 2021 - 2033 (USD Million)
• Table 14 U.S. Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Biomarker, 2021 - 2033 (USD Million)
• Table 15 U.S. Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Technology, 2021 - 2033 (USD Million)
• Table 16 U.S. Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
• Table 17 Canada Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Cancer, 2021 - 2033 (USD Million)
• Table 18 Canada Liquid Biopsy for Early Cancer Detection and Monitoring Market, by Biomarker, 2021 - 2033 (USD Million)
• Table 19 Canada Liquid Biopsy for Early Cancer Detection and Monitoring Market, by Technology, 2021 - 2033 (USD Million)
• Table 20 Canada Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
• Table 21 Mexico liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
• Table 22 Mexico Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Biomarker, 2021 - 2033 (USD Million)
• Table 23 Mexico Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Technology, 2021 - 2033 (USD Million)
• Table 24 Mexico Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
• Table 25 Europe liquid biopsy for early cancer detection and monitoring market, by country, 2021 - 2033 (USD Million)
• Table 26 Europe liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
• Table 27 Europe Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Biomarker, 2021 - 2033 (USD Million)
• Table 28 Europe Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Technology, 2021 - 2033 (USD Million)
• Table 29 Europe Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
• Table 30 UK liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
• Table 31 UK Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Biomarker, 2021 - 2033 (USD Million)
• Table 32 UK Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Technology, 2021 - 2033 (USD Million)
• Table 33 UK Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
• Table 34 Germany liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
• Table 35 Germany Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Biomarker, 2021 - 2033 (USD Million)
• Table 36 Germany Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Technology, 2021 - 2033 (USD Million)
• Table 37 Germany Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
• Table 38 France liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
• Table 39 France Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Biomarker, 2021 - 2033 (USD Million)
• Table 40 France Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Technology, 2021 - 2033 (USD Million)
• Table 41 France Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
• Table 42 Italy liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
• Table 43 Italy Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Biomarker, 2021 - 2033 (USD Million)
• Table 44 Italy Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Technology, 2021 - 2033 (USD Million)
• Table 45 Italy Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
• Table 46 Spain liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
• Table 47 Spain Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Biomarker, 2021 - 2033 (USD Million)
• Table 48 Spain Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Technology, 2021 - 2033 (USD Million)
• Table 49 Spain Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
• Table 50 Sweden liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
• Table 51 Sweden Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Biomarker, 2021 - 2033 (USD Million)
• Table 52 Sweden Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Technology, 2021 - 2033 (USD Million)
• Table 53 Sweden Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
• Table 54 Norway liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
• Table 55 Norway Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Biomarker, 2021 - 2033 (USD Million)
• Table 56 Norway Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Technology, 2021 - 2033 (USD Million)
• Table 57 Norway Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
• Table 58 Denmark liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
• Table 59 Denmark Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Biomarker, 2021 - 2033 (USD Million)
• Table 60 Denmark Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Technology, 2021 - 2033 (USD Million)
• Table 61 Denmark Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
• Table 62 Asia Pacific liquid biopsy for early cancer detection and monitoring market, by country, 2021 - 2033 (USD Million)
• Table 63 Asia Pacific liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
• Table 64 Asia Pacific Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Biomarker, 2021 - 2033 (USD Million)
• Table 65 Asia Pacific Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Technology, 2021 - 2033 (USD Million)
• Table 66 Asia Pacific Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
• Table 67 Japan liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
• Table 68 Japan Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Biomarker, 2021 - 2033 (USD Million)
• Table 69 Japan Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Technology, 2021 - 2033 (USD Million)
• Table 70 Japan Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
• Table 71 China liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
• Table 72 China liquid biopsy for early cancer detection and monitoring market, by Biomarker, 2021 - 2033 (USD Million)
• Table 73 China liquid biopsy for early cancer detection and monitoring market, by Technology, 2021 - 2033 (USD Million)
• Table 74 China liquid biopsy for early cancer detection and monitoring market, by End Use, 2021 - 2033 (USD Million)
• Table 75 India liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
• Table 76 India liquid biopsy for early cancer detection and monitoring market, by Biomarker, 2021 - 2033 (USD Million)
• Table 77 India liquid biopsy for early cancer detection and monitoring market, by Technology, 2021 - 2033 (USD Million)
• Table 78 India liquid biopsy for early cancer detection and monitoring market, by End Use, 2021 - 2033 (USD Million)
• Table 79 Australia liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
• Table 80 Australia liquid biopsy for early cancer detection and monitoring market, by Biomarker, 2021 - 2033 (USD Million)
• Table 81 Australia liquid biopsy for early cancer detection and monitoring market, by Technology, 2021 - 2033 (USD Million)
• Table 82 Australia liquid biopsy for early cancer detection and monitoring market, by End Use, 2021 - 2033 (USD Million)
• Table 83 Thailand liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
• Table 84 Thailand liquid biopsy for early cancer detection and monitoring market, by Biomarker, 2021 - 2033 (USD Million)
• Table 85 Thailand liquid biopsy for early cancer detection and monitoring market, by Technology, 2021 - 2033 (USD Million)
• Table 86 Thailand liquid biopsy for early cancer detection and monitoring market, by End Use, 2021 - 2033 (USD Million)
• Table 87 South Korea liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
• Table 88 South Korea liquid biopsy for early cancer detection and monitoring market, by Biomarker, 2021 - 2033 (USD Million)
• Table 89 South Korea liquid biopsy for early cancer detection and monitoring market, by Technology, 2021 - 2033 (USD Million)
• Table 90 South Korea liquid biopsy for early cancer detection and monitoring market, by End Use, 2021 - 2033 (USD Million)
• Table 91 Latin America liquid biopsy for early cancer detection and monitoring market, by country, 2021 - 2033 (USD Million)
• Table 92 Latin America liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
• Table 93 Latin America liquid biopsy for early cancer detection and monitoring market, by Biomarker, 2021 - 2033 (USD Million)
• Table 94 Latin America liquid biopsy for early cancer detection and monitoring market, by Technology, 2021 - 2033 (USD Million)
• Table 95 Latin America liquid biopsy for early cancer detection and monitoring market, by End Use, 2021 - 2033 (USD Million)
• Table 96 Brazil liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
• Table 97 Brazil liquid biopsy for early cancer detection and monitoring market, by Biomarker, 2021 - 2033 (USD Million)
• Table 98 Brazil liquid biopsy for early cancer detection and monitoring market, by Technology, 2021 - 2033 (USD Million)
• Table 99 Brazil liquid biopsy for early cancer detection and monitoring market, by End Use, 2021 - 2033 (USD Million)
• Table 100 Argentina liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
• Table 101 Argentina liquid biopsy for early cancer detection and monitoring market, by Biomarker, 2021 - 2033 (USD Million)
• Table 102 Argentina liquid biopsy for early cancer detection and monitoring market, by Technology, 2021 - 2033 (USD Million)
• Table 103 Argentina liquid biopsy for early cancer detection and monitoring market, by End Use, 2021 - 2033 (USD Million)
• Table 104 MEA liquid biopsy for early cancer detection and monitoring market, by country, 2021 - 2033 (USD Million)
• Table 105 MEA liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
• Table 106 MEA liquid biopsy for early cancer detection and monitoring market, by Biomarker, 2021 - 2033 (USD Million)
• Table 107 MEA liquid biopsy for early cancer detection and monitoring market, by Technology, 2021 - 2033 (USD Million)
• Table 108 MEA liquid biopsy for early cancer detection and monitoring market, by End Use, 2021 - 2033 (USD Million)
• Table 109 South Africa liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
• Table 110 South Africa liquid biopsy for early cancer detection and monitoring market, by Biomarker, 2021 - 2033 (USD Million)
• Table 111 South Africa liquid biopsy for early cancer detection and monitoring market, by Technology, 2021 - 2033 (USD Million)
• Table 112 South Africa liquid biopsy for early cancer detection and monitoring market, by End Use, 2021 - 2033 (USD Million)
• Table 113 Saudi Arabia liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
• Table 114 Saudi Arabia liquid biopsy for early cancer detection and monitoring market, by Biomarker, 2021 - 2033 (USD Million)
• Table 115 Saudi Arabia liquid biopsy for early cancer detection and monitoring market, by Technology, 2021 - 2033 (USD Million)
• Table 116 Saudi Arabia liquid biopsy for early cancer detection and monitoring market, by End Use, 2021 - 2033 (USD Million)
• Table 117 UAE liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
• Table 118 UAE liquid biopsy for early cancer detection and monitoring market, by Biomarker, 2021 - 2033 (USD Million)
• Table 119 UAE liquid biopsy for early cancer detection and monitoring market, by Technology, 2021 - 2033 (USD Million)
• Table 120 UAE liquid biopsy for early cancer detection and monitoring market, by End Use, 2021 - 2033 (USD Million)
• Table 121 Kuwait liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD)
• Table 122 Kuwait liquid biopsy for early cancer detection and monitoring market, by Biomarker, 2021 - 2033 (USD Million)
• Table 123 Kuwait liquid biopsy for early cancer detection and monitoring market, by Technology, 2021 - 2033 (USD Million)
• Table 124 Kuwait liquid biopsy for early cancer detection and monitoring market, by End Use, 32021 - 2033 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Market summary
• Fig. 4 Market segmentation & scope
• Fig. 5 Market size and growth prospects
• Fig. 6 Global liquid biopsy for early cancer detection and monitoring market- Key market driver analysis
• Fig. 7 Global liquid biopsy for early cancer detection and monitoring market- Key market restraint analysis
• Fig. 8 Penetration & growth prospect mapping
• Fig. 9 Global liquid biopsy for early cancer detection and monitoring market- Porter's analysis
• Fig. 10 Global liquid biopsy for early cancer detection and monitoring market- PESTEL analysis
• Fig. 11 Global liquid biopsy for early cancer detection and monitoring marketbiomarker outlook key takeaways
• Fig. 12 Global liquid biopsy for early cancer detection and monitoring market: biomarker movement analysis
• Fig. 13 Circulating Tumor DNA (ctDNA) market estimates, 2021 - 2033 (USD Million)
• Fig. 14 Circulating Tumor Cells (CTCs) market estimates, 2021 - 2033 (USD Million)
• Fig. 15 Exosomes/Microvesicles market estimates, 2021 - 2033 (USD Million)
• Fig. 16 Circulating Proteins market estimates, 2021 - 2033 (USD Million)
• Fig. 17 Global liquid biopsy for early cancer detection and monitoring markettechnology outlook key takeaways
• Fig. 18 Global liquid biopsy for early cancer detection and monitoring market: technology movement analysis
• Fig. 19 NGS (Next-Generation Sequencing) market estimates, 2021 - 2033 (USD Million)
• Fig. 20 PCR-based assays (Digital PCR, RT-PCR) market estimates, 2021 - 2033 (USD Million)
• Fig. 21 Microarray market estimates, 2021 - 2033 (USD Million)
• Fig. 22 Epigenomics / Methylation assays market estimates, 2021 - 2033 (USD Million)
• Fig. 23 Others market estimates, 2021 - 2033 (USD Million)
• Fig. 24 Global liquid biopsy for early cancer detection and monitoring marketcancer outlook key takeaways
• Fig. 25 Global liquid biopsy for early cancer detection and monitoring market: cancer movement analysis
• Fig. 26 Lung cancer market estimates, 2021 - 2033 (USD Million)
• Fig. 27 Breast cancer market estimates, 2021 - 2033 (USD Million)
• Fig. 28 Colorectal cancer market estimates, 2021 - 2033 (USD Million)
• Fig. 29 Prostate cancer market estimates, 2021 - 2033 (USD Million)
• Fig. 30 Others market estimates, 2021 - 2033 (USD Million)
• Fig. 31 Global liquid biopsy for early cancer detection and monitoring marketend use outlook key takeaways
• Fig. 32 Global liquid biopsy for early cancer detection and monitoring market: end use movement analysis
• Fig. 33 Hospitals market estimates, 2021 - 2033 (USD Million)
• Fig. 34 Diagnostic Laboratories market estimates, 2021 - 2033 (USD Million)
• Fig. 35 Others market estimates, 2021 - 2033 (USD Million)
• Fig. 36 Regional marketplace: Key takeaways
• Fig. 37 Global liquid biopsy for early cancer detection and monitoring market: Regional movement analysis
• Fig. 38 North America liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
• Fig. 39 U.S. liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
• Fig. 40 Canada liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
• Fig. 41 Mexico liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
• Fig. 42 Europe liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
• Fig. 43 UK liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
• Fig. 44 Germany liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
• Fig. 45 France liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
• Fig. 46 Spain liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
• Fig. 47 Italy liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
• Fig. 48 Denmark liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
• Fig. 49 Sweden liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
• Fig. 50 Norway liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
• Fig. 51 Asia Pacific liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
• Fig. 52 Japan liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
• Fig. 53 China liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
• Fig. 54 India liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
• Fig. 55 South Korea liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
• Fig. 56 Australia liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
• Fig. 57 Thailand liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
• Fig. 58 Latin America liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
• Fig. 59 Brazil liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
• Fig. 60 Argentina liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
• Fig. 61 MEA liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
• Fig. 62 South Africa liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
• Fig. 63 Saudi Arabia liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
• Fig. 64 UAE liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
• Fig. 65 Kuwait liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
• Fig. 66 Strategy framework

Liquid Biopsy For Early Cancer Detection And Monitoring Market Summary

The global liquid biopsy for early cancer detection and monitoring market size was estimated at USD 2.23 billion in 2024 and is projected to reach USD 6.20 billion by 2033, growing at a CAGR of 12.14% from 2025 to 2033. This market focuses on diagnostic solutions designed for the early and accurate detection of various cancers, enabling timely intervention and improved patient outcomes.

Technologies within this segment include platforms for analyzing circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers from body fluids, offering a less invasive alternative to tissue biopsies. These solutions are increasingly integrated into oncology practices for early detection, therapy selection, and disease monitoring across clinical and research environments.

The adoption of liquid biopsy is supported by rising cancer incidence and the growing need for non-invasive methods that allow frequent monitoring with minimal discomfort to patients. The ability to detect tumor-related genetic changes in real time provides oncologists with valuable information for treatment decisions and early intervention strategies.

Moreover, the adoption of liquid biopsy is increasing as the field moves toward precision oncology, where genomic and molecular insights inform treatment decisions and long-term care. High-sensitivity techniques supported by next-generation sequencing, digital PCR workflows, and advancing bioinformatics tools help detect low-frequency variants, minimal residual disease, and emerging resistance signals. Additionally, efforts in multi-cancer early detection and assay panels that analyze multiple biomarkers such as DNA, RNA fragments, epigenetic signatures, and extracellular vesicle content are broadening clinical applications from late-stage management to risk assessment and population-level screening.

Furthermore, the market is shaped by evidence-generation programs, regulatory support, and payer assessments that focus on clinical value and cost-effectiveness compared to traditional tissue-based methods. Challenges still exist, such as variations in assay performance across platforms, a lack of standardization in sample collection and analysis, and difficulties in interpreting weak signals in early disease stages. Limited reimbursement in some regions also impacts accessibility. Ongoing clinical trials, real-world studies, and data-sharing initiatives are expected to bring clarity, improve guidelines, and promote wider adoption of liquid biopsy for early detection and continuous cancer monitoring.

Innovation in liquid biopsy for early detection and monitoring emphasizes accuracy, accessibility, and clinical applicability. Multi-omics integration, AI-driven interpretation, and advanced sequencing transform detection and tracking processes, enabling higher sensitivity for early-stage disease and more personalized treatment planning.

Developments such as multi-cancer detection assays and near-patient platforms aim to extend liquid biopsies outside centralized facilities, enhancing convenience and supporting large-scale screening initiatives. Progress in minimal residual disease detection and continuous monitoring is expected to drive broader clinical uptake and strengthen liquid biopsy's role in oncology care.

Global Liquid Biopsy For Early Cancer Detection And Monitoring Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global liquid biopsy for early cancer detection and monitoring market based on biomarker, technology, cancer, end use, and region:

• Biomarker Outlook (USD Million; 2021 - 2033)
• Circulating Tumor DNA (ctDNA)
• Circulating Tumor Cells (CTCs)
• Exosomes/Microvesicles
• Circulating Proteins
• Technology Outlook (USD Million; 2021 - 2033)
• NGS (Next-Generation Sequencing)
• PCR-based assays (Digital PCR, RT-PCR)
• Microarray
• Epigenomics / Methylation assays
• Others
• Cancer Outlook (USD Million; 2021 - 2033)
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Others
• End Use Outlook (USD Million; 2021 - 2033)
• Hospitals
• Diagnostic Laboratories
• Others
• Regional Outlook (USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Methodology And Scope

• 1.1. Market Segmentation And Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Biomarker Segment
    • 1.1.1.2. Technology Segment
    • 1.1.1.3. Cancer Segment
    • 1.1.1.4. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates And Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. Gvr's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information Or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List Of Secondary Sources
• 1.11. List Of Abbreviations

Chapter 2. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Biomarker And Technology Snapshot
• 2.3. Cancer Snapshot
• 2.4. End Use Snapshot
• 2.5. Competitive Landscape Snapshot

Chapter 3. Liquid Biopsy For Early Cancer Detection And Monitoring Market Variables, Trends, & Scope

• 3.1. Market Segmentation And Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Growing Demand For Non-Invasive Cancer Screening
  • 3.4.2. Integration Of Advanced Technologies
  • 3.4.3. Increasing Clinical Adoption And Regulatory Approvals
• 3.5. Market Restraint Analysis
  • 3.5.1. High Cost Of Liquid Biopsy Tests And Infrastructure
  • 3.5.2. Analytical And Clinical Validation Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. Pestle Analysis
• 3.8. Pipeline Analysis

Chapter 4. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Biomarker Estimates & Trend Analysis

• 4.1. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Biomarker Movement Analysis
• 4.2. Circulating Tumor Dna (Ctdna)
  • 4.2.1. Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 4.3. Circulating Tumor Cells (Ctcs)
  • 4.3.1. Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 4.4. Exosomes/Microvesicles
  • 4.4.1. Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 4.5. Circulating Proteins
  • 4.5.1. Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Technology Estimates & Trend Analysis

• 5.1. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Technology Movement Analysis
• 5.2. Ngs (Next-Generation Sequencing)
  • 5.2.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
• 5.3. Pcr-Based Assays (Digital Pcr, Rt-Pcr)
  • 5.3.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
• 5.4. Microarray
  • 5.4.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
• 5.5. Epigenomics / Methylation Assays
  • 5.5.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
• 5.6. Others
  • 5.6.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Cancer Estimates & Trend Analysis

• 6.1. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Cancer Movement Analysis
• 6.2. Lung Cancer
  • 6.2.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
• 6.3. Breast Cancer
  • 6.3.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
• 6.4. Colorectal Cancer
  • 6.4.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
• 6.5. Prostate Cancer
  • 6.5.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Liquid Biopsy For Early Cancer Detection And Monitoring Market: End Use Estimates & Trend Analysis

• 7.1. Liquid Biopsy For Early Cancer Detection And Monitoring Market: End Use Movement Analysis
• 7.2. Hospitals
  • 7.2.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
• 7.3. Diagnostic Laboratories
  • 7.3.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
• 7.4. Others
  • 7.4.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Regional Business Analysis

• 8.1. Regional Market Snapshot
• 8.2. North America
  • 8.2.1. North America Liquid Biopsy For Early Cancer Detection And Monitoring Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. U.S. Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.2.2.2. Key Country Dynamics
    • 8.2.2.3. Regulatory Framework
    • 8.2.2.4. Reimbursement Scenario
    • 8.2.2.5. Competitive Scenario
  • 8.2.3. Canada
    • 8.2.3.1. Canada Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.2.3.2. Key Country Dynamics
    • 8.2.3.3. Regulatory Framework
    • 8.2.3.4. Reimbursement Scenario
    • 8.2.3.5. Competitive Scenario
  • 8.2.4. Mexico
    • 8.2.4.1. Mexico Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.2.4.2. Key Country Dynamics
    • 8.2.4.3. Regulatory Framework
    • 8.2.4.4. Reimbursement Scenario
    • 8.2.4.5. Competitive Scenario
• 8.3. Europe
  • 8.3.1. Europe Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. UK Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.3.2.2. Key Country Dynamics
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. Reimbursement Scenario
    • 8.3.2.5. Competitive Scenario
  • 8.3.3. Germany
    • 8.3.3.1. Germany Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.3.3.2. Key Country Dynamics
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Reimbursement Scenario
    • 8.3.3.5. Competitive Scenario
  • 8.3.4. Spain
    • 8.3.4.1. Spain Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.3.4.2. Key Country Dynamics
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Reimbursement Scenario
    • 8.3.4.5. Competitive Scenario
  • 8.3.5. France
    • 8.3.5.1. France Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.3.5.2. Key Country Dynamics
    • 8.3.5.3. Regulatory Framework
    • 8.3.5.4. Reimbursement Scenario
    • 8.3.5.5. Competitive Scenario
  • 8.3.6. Italy
    • 8.3.6.1. Italy Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.3.6.2. Key Country Dynamics
    • 8.3.6.3. Regulatory Framework
    • 8.3.6.4. Reimbursement Scenario
    • 8.3.6.5. Competitive Scenario
  • 8.3.7. Denmark
    • 8.3.7.1. Denmark Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.3.7.2. Key Country Dynamics
    • 8.3.7.3. Regulatory Framework
    • 8.3.7.4. Reimbursement Scenario
    • 8.3.7.5. Competitive Scenario
  • 8.3.8. Sweden
    • 8.3.8.1. Sweden Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.3.8.2. Key Country Dynamics
    • 8.3.8.3. Regulatory Framework
    • 8.3.8.4. Reimbursement Scenario
    • 8.3.8.5. Competitive Scenario
  • 8.3.9. Norway
    • 8.3.9.1. Norway Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.3.9.2. Key Country Dynamics
    • 8.3.9.3. Regulatory Framework
    • 8.3.9.4. Reimbursement Scenario
    • 8.3.9.5. Competitive Scenario
• 8.4. Asia Pacific
  • 8.4.1. Asia-Pacific Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Japan Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.4.2.2. Key Country Dynamics
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Scenario
    • 8.4.2.5. Competitive Scenario
  • 8.4.3. China
    • 8.4.3.1. China Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.4.3.2. Key Country Dynamics
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Scenario
    • 8.4.3.5. Competitive Scenario
  • 8.4.4. India
    • 8.4.4.1. India Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.4.4.2. Key Country Dynamics
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Scenario
    • 8.4.4.5. Competitive Scenario
  • 8.4.5. South Korea
    • 8.4.5.1. South Korea Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.4.5.2. Key Country Dynamics
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Reimbursement Scenario
    • 8.4.5.5. Competitive Scenario
  • 8.4.6. Thailand
    • 8.4.6.1. Thailand Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.4.6.2. Key Country Dynamics
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Reimbursement Scenario
    • 8.4.6.5. Competitive Scenario
  • 8.4.7. Australia
    • 8.4.7.1. Australia Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.4.7.2. Key Country Dynamics
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Reimbursement Scenario
    • 8.4.7.5. Competitive Scenario
• 8.5. Latin America
  • 8.5.1. Latin America Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Brazil Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.5.2.2. Key Country Dynamics
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Scenario
    • 8.5.2.5. Competitive Scenario
  • 8.5.3. Argentina
    • 8.5.3.1. Argentina Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.5.3.2. Key Country Dynamics
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Scenario
    • 8.5.3.5. Competitive Scenario
• 8.6. MEA
  • 8.6.1. MEA Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. South Africa Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.6.2.2. Key Country Dynamics
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Scenario
    • 8.6.2.5. Competitive Scenario
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Saudi Arabia Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.6.3.2. Key Country Dynamics
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Scenario
    • 8.6.3.5. Competitive Scenario
  • 8.6.4. UAE
    • 8.6.4.1. UAE Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.6.4.2. Key Country Dynamics
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Scenario
    • 8.6.4.5. Competitive Scenario
  • 8.6.5. Kuwait
    • 8.6.5.1. Kuwait Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.6.5.2. Key Country Dynamics
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Scenario
    • 8.6.5.5. Competitive Scenario

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
  • 9.2.1. New Biomarker Launch
  • 9.2.2. Partnerships
  • 9.2.3. Acquisition
  • 9.2.4. Collaboration
  • 9.2.5. Funding
• 9.3. Key Company Market Share Analysis, 2024
• 9.4. Company Heat Map Analysis
• 9.5. Company Profiles
  • 9.5.1. Grail, Inc.
    • 9.5.1.1. Company Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Biomarker Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Exact Sciences Corporation
    • 9.5.2.1. Company Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Biomarker Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Anchordx
    • 9.5.3.1. Company Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Biomarker Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. Burning Rock Biotech Limited
    • 9.5.4.1. Company Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Biomarker Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Genecast
    • 9.5.5.1. Company Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Biomarker Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. Guardant Health
    • 9.5.6.1. Company Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Biomarker Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Myriad Genetics, Inc.
    • 9.5.7.1. Company Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Biomarker Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. Elypta Ab
    • 9.5.8.1. Company Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Biomarker Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Lucence Health Inc.
    • 9.5.9.1. Company Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Biomarker Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. Freenome Holdings, Inc.
    • 9.5.10.1. Company Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Biomarker Benchmarking
    • 9.5.10.4. Strategic Initiatives
  • 9.5.11. Oncimmune
    • 9.5.11.1. Company Overview
    • 9.5.11.2. Financial Performance
    • 9.5.11.3. Biomarker Benchmarking
    • 9.5.11.4. Strategic Initiatives